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Effects of specific COX-2-inhibition on renin release and renal
and systemic prostanoid synthesis in healthy volunteers.
Background. The renin-angiotensin system plays a critical
role in cardiovascular function, but little is known about the
effects of specific cyclooxygenase 2 (COX-2) inhibition on this
system in healthy humans under physiologic conditions.
Methods. Twenty-one healthy female volunteers received, in
a randomized, double-blind, crossover study, celecoxib 200 mg
twice a day, indomethacin 50 mg three times a day, or placebo
for 4 days and a single dose, each, on day 5. On day 5 of each
treatment, the following parameters were assessed with sub-
jects in an upright position before and after administration of
20 mg furosemide intravenously: plasma renin activity (PRA),
plasma aldosterone, serum and urine electrolytes, and creati-
nine. Index metabolites of prostanoids were analyzed by gas
chromatography-tandem mass spectrometry in 24-hour urine
on day 4 and in 2-hour urines before and after furosemide
administration.
Results. Baseline and furosemide-stimulated PRA were re-
duced to a similar degree by celecoxib and indomethacin.
Plasma aldosterone and urinary excretion of potassium showed
changes consistent with the alteration of PRA. Urinary ex-
cretion rates of prostaglandin E2, (PGE2), 7a-hydroxy-5,
11-diketotetranor-prosta-1,16-dioic acid (PGE-M), and 2,3-
dinor-thromboxane B2 (TxB2) were not reduced by celecoxib,
whereas indomethacin led to a decrease of 40%, 45%, and 80%,
respectively. Both active treatments inhibited urinary excretion
of 2,3-dinor-6-keto-PGF1a and 6-keto-PGF1a by 60% and 40%,
respectively.
Conclusion. Renin-release in healthy humans with normal
salt intake is COX-2 dependent. While COX-1 is critical for
renal and systemic PGE2 production, renal prostacyclin syn-
thesis is apparently COX-2 dependent. Finally, the previously
demonstrated shift of the thromboxane-prostacyclin balance to-
ward prothrombotic thromboxane by specific COX-2 inhibition
is confirmed.
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The discovery of the cyclooxygenase (COX) isoen-
zymes (i.e., the constitutive COX-1, serving homeostatic
prostanoid synthesis, and the inducible COX-2, responsi-
ble for proinflammatory prostanoid production) ushered
in a new generation of nonsteroidal anti-inflammatory
drugs (NSAIDs) with the promise of fewer side effects
[1, 2]. In the last few years it has become evident that
specific COX-2 inhibitors have significantly less gastroin-
testinal toxicity and no effects on platelet aggregation
[3]. However, we also learned that there is no reduction
in risk for renal side effects and that there are unexpected
cardiovascular risks [3, 4].
In the human kidney prostaglandin E2 (PGE2) and
prostacyclin are the predominant prostanoids, playing an
important role for renal function: Maintenance of renal
blood flow (RBF) and glomerular filtration rate (GFR),
inhibition of tubular sodium reabsorption, antagonism
of antidiuretic hormone (ADH) action, and mediation of
renin secretion [4]. Thus, inhibition of renal prostanoid
synthesis by NSAIDs causes reduction in RBF and GFR
with renal failure as possible consequence, sodium and
water retention, water intoxication, and hyperkalemia
[4]. As far as the responsible COX isoenzymes for these
prostanoid-controlled mechanisms in the human kidney
are concerned, clinical studies with specific COX-2 in-
hibitors revealed that COX-2 is the critical enzyme for
sodium excretion [4]. For renal hemodynamics, the evi-
dence points to COX-1 as the predominant enzyme [4].
An area of uncertainty is the role of COX-2 for antago-
nism of ADH and renin release in the human kidney.
Regarding renin release, there is clear evidence that
in rodents COX-2, but not COX-1, is constitutively ex-
pressed in the macula densa [5]. Moreover, regulation of
COX-2 expression by dietary salt and inhibition of renin
secretion by COX-2–specific drugs is well described [5].
In contrast, there is limited and confounding information
on the situation in humans. Nantel et al [6] examined
the distribution of COX isoenzymes in kidneys obtained
from adults without renal or cardiovascular disease and
reported the presence of COX-2 in the macula densa,
which was more evident in kidney specimens obtained
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from subjects aged ≥48 years (five of five) than in sub-
jects <40 years (two of five). Furthermore, Ko¨mhoff et al
[7] found COX-2 immunoreactive protein in the mac-
ula densa of a patient with congestive heart failure, but
not in patients without underlying renal or cardiovascu-
lar pathology. Other reports were negative for COX-2 in
the macula densa of healthy men or in transplanted kid-
neys undergoing rejection [8–10]. Notably, COX-1 was
never observed in the macula densa of humans or other
mammals [4–10]. Summarizing these results, there seems
to be a low level, difficult to detect, constitutive expres-
sion of COX-2 in the macula densa in healthy humans;
this COX-2 is apparently increased in conditions with en-
hanced sympathetic drive and in elderly persons, where
up-regulation of COX-2 may represent a compensatory
mechanism for the physiological decrease of basal plasma
renin activity (PRA) [6]. The functional role of this low
level constitutive COX-2 expression in the macula densa
is poorly described. Incidentally, a study with flosulide,
a drug later classified as specific COX-2 inhibitor which
was not further developed, showed suppression of PRA
3 hours after oral administration of furosemide in hu-
mans [11]. Our group previously investigated the effects
of the preferential COX-2 inhibitor meloxicam on PRA
[12]. We found that meloxicam inhibited the furosemide
stimulated PRA as effectively as indomethacin, suggest-
ing that the COX isoenzyme responsible for renin release
in humans is COX-2 [12]. However, verification of these
results by a specific COX-2 inhibitor was lacking. Re-
cently, Kammerl et al [13] demonstrated in healthy vol-
unteers that renin secretion stimulated by a low sodium
diet for 8 days was completely reversed by the specific
COX-2 inhibitor rofecoxib. However, while this study de-
sign clearly proves the functional role of induced COX-2
expression as adaptive mechanism under sodium deple-
tion, no conclusions on the physiologic situation with
a very low, if any, constitutive COX-2 expression are
possible.
The primary objective of the present study was to as-
sess the effects of the specific COX-2 inhibitor celecoxib
on the PRA in healthy volunteers under physiologic con-
ditions before and after furosemide stimulation and to
compare it with the effects of indomethacin, an unselec-
tive COX-inhibitor [3]. The intravenous bolus injection
of furosemide achieves, by a tubular effect at the mac-
ula densa, an immediate prostanoid-mediated stimula-
tion of renin release, independent of the later occurring
sodium/water depletion [14], which leads to enhanced
sympathetic drive and COX-2 induction. In addition
to PRA, the secondary parameters plasma aldosterone,
potassium, sodium, and creatinine in serum and urine as
well as body weight were determined. To evaluate the re-
lationship between specific COX-2 inhibition and phys-
iologic prostanoid synthesis, the following prostanoids
were assessed: (1) Urinary excretion of PGE2, reflect-
ing renal PGE2 synthesis [15]; (2) urinary excretion
of 7a-hydroxy-5,11-diketotetranor-prosta-1,16-dioic acid
(PGE-M), which appears as the main metabolite of PGE2
in the urine and reflects whole body PGE2 synthesis [16];
(3) urinary excretion of 2,3-dinor-6-keto-PGF1a and 6-
keto-PGF1a , which are the main metabolites of prosta-
cyclin, reflecting total body and in part (6-keto-PGF1a)
renal prostacyclin synthesis [17]; (4) urinary excretion
of 2,3-dinor-thromboxane (Tx) B2, reflecting total body
thromboxane synthesis [18], which is COX-1 dependent
[3].
METHODS
Study subjects
Twenty-one healthy women, mean age 23.6 ± SD
2.6 years (age range 20 to 31 years) were included in this
study. Inclusion criteria were female, age 18 to 35 years,
healthy, intake of oral contraceptives, willingness to ob-
serve sexual abstinence during the study to avoid con-
tamination of urine samples by seminal fluid (see below),
and written informed consent. Exclusion criteria were
acute or chronic diseases, medical history of ulcer disease,
known intolerance or allergy to NSAIDs, pregnancy, lac-
tation, drug dependence, alcohol or nicotine abuse, and
intake of NSAIDs or other drugs than oral contracep-
tives. Inclusion and exclusion criteria were controlled
by clinical history, physical examination, and laboratory
screening. The study was approved by the Ethics Com-
mittee of the Medizinische Hochschule Hannover. The
study was performed in women of childbearing age, since
in males the urinary excretion of PGE2 is not a valid index
parameter for the renal prostaglandin synthesis because
of high amounts of PGE2 in seminal fluid [15]. Further-
more, urinary excretion of PGE-M shows a greater in-
terindividual variability in males and is age-dependent in
males and females [16].
Study design
The volunteers received in a randomized, double-
blind, double-dummy, three-period crossover design,
celecoxib 200 mg twice a day (8:00 a.m. and 8:00 p.m.), in-
domethacin 50 mg three times a day (8:00 a.m., 2:00 p.m.,
and 8:00 p.m.) or placebo for 4 days (in the indomethacin
phase day 1 placebo, days 2 to 4 indomethacin) and a
single dose of each medication at 8:00 a.m. on the day 5.
The study medication was obtained from the European
Clinical Pharmacy Department of Pharmacia (Feucht,
Germany). Between the three study periods were two
drug-free washout periods of 4 days’ duration. The dura-
tion of the test and the washout periods were chosen so
that the concentrations of celecoxib and indomethacin,
respectively, were in steady state on the penultimate day
(day 4) of each treatment period, an overlap of the two
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medications was not possible and after the furosemide
stimulation test (see below) the electrolyte-water balance
was reestablished. The volunteers were kept on their nor-
mal Western diet with an estimated daily sodium intake
of 2.7 to 3.2 g (117 to 139 mmol/day); dietary sodium
intake and reestablishment of sodium balance were con-
trolled by measurement of 24-hour urinary sodium ex-
cretion (see Results section).
Commencement of study medication was adapted to
the apparent menstrual cycle under hormonal contracep-
tion (start on day 5 of the apparent menstrual cycle, the
last day of the last treatment period on day 27). Com-
pliance was controlled by observation of drug intake at
8:00 a.m. in the study center, intake at 2:00 p.m. and
8:00 p.m. was controlled by telephone.
Body weight was measured on each study visit at
10:25 a.m. On day 4 of each treatment period 24-hour
urine was collected for determination of prostanoids,
potassium, sodium, and creatinine. On day 5 of each
treatment period the volunteers received a standardized
breakfast at 7:30 a.m. (two pieces of wheat toast, 25 g
butter, jam, and 300 mL water). After placement of a
21 gauge venous cannula at the forearm at 10:00 a.m., the
volunteers were kept in an upright position. At 10:55 a.m.,
blood samples were taken for determination of PRA, al-
dosterone, potassium, sodium, and creatinine. Five min-
utes later, 20 mg of furosemide was given intravenously
as a bolus, and blood for measurement of PRA, aldos-
terone, potassium, sodium, and creatinine was collected
5, 10, 30, 60, and 120 minutes after furosemide injection.
Urine was collected 2 hours before and after furosemide
administration for determination of prostanoids, potas-
sium, sodium, and creatinine.
Analytic methods
PRA. Blood was collected in a 5 mL ethylenedi-
aminetetraacetic acid (EDTA) monovette, immediately
chilled on ice, and the plasma prepared by centrifugation.
PRA was determined by a commercially available ra-
dioimmunoassay (RENCTK, P2721) (Sorin Biomedica,
Saluggia, Italy).
Plasma aldosterone concentration. Blood was col-
lected in a 5 mL heparin monovette, processed as de-
scribed for PRA, and aldosterone was measured by
a commercially available radioimmunoassay (Coat-A-
Count Aldosterone) (Diagnostic Products Corporation,
Los Angeles, CA, USA).
Prostanoid excretion in urine. The determination of
PGE2, PGE-M, 2,3-dinor-6-keto-PGF1a , 6-keto-PGF1a ,
and 2,3-dinor-TxB2 in urine was carried out by gas
chromatography-tandem mass spectrometry with use of
stable isotope-labeled internal standards as described by
us previously [19].
Sodium, potassium, and creatinine in serum and urine.
These analyses were carried out in laboratory rou-
tine by ion-selective electrode and spectrophotometry,
respectively.
Statistical analysis
All data are given as the mean ± standard deviation
(SD) or standard error (SE) (Figs. 1 to 7). Carryover
and sequence effects were analyzed as described by Hills
and Armitage [20]; neither carryover nor sequence effects
were observed. Statistical significance of differences was
analyzed by Student paired two-tailed t test with an a of
0.05 and a b level of 0.2. The study was powered to detect a
difference of 0.90 ng/mL/hour in PRA and 25.8 nmol/mol
creatinine in urinary PGE2 excretion (N = 16, a = 0.05,
b = 0.2). The analyses were performed with SPSS for
Windows (release 11.0.1., SPSS Inc., Chicago, IL, USA).
RESULTS
Volunteers
Twenty-one volunteers participated in the study; 16
subjects completed the study in accordance with the
study protocol. Five volunteers dropped out. Volunteer 2
dropped out because of protocol violation. Volunteer 4
experienced repeated fainting after the first furosemide
injection and was excluded. Volunteer 16 withdrew on
the last day of the last treatment period for personal rea-
sons; however, as collection of 24-hour urines for all three
medications was completed, data from volunteer 16 were
included in statistical analysis of prostanoid excretion in
24-hour urine. Volunteer 15 was withdrawn retroactively,
because of thrombocytosis at the final visit, which was di-
agnosed as beginning chronic myeloproliferative disease,
thus fulfilling criteria of a serious adverse event. Volun-
teer 19 developed an acute hearing loss during the first
washout period and was hospitalized, thus fulfilling the
serious adverse event criteria. The last drug intake (code
break for 19 revealed celecoxib) was 3 days ago. Both se-
rious adverse events were judged to be unrelated to the
study medication.
PRA
The results for PRA are given in Figure 1. In the
placebo phase, the baseline PRA level was 2.92 ± 1.59 ng/
mL/hour. The normal range for PRA in the radioim-
munoassay used is 1.5 to 5.7 ng/mL/hour in upright
position and 0.2 to 2.8 ng/mL/hour in supine posi-
tion for a sodium intake of 100 to 150 mmol/day.
Furosemide led to a marked increase of PRA with a
maximum of 4.84 ± 3.34 ng/mL/hour at 60 minutes. Cele-
coxib caused an inhibition of baseline (1.63 ± 0.64 ng/
mL/hour) and furosemide-stimulated PRA (maximum
2.68 ± 1.53 ng/mL/hour at 30 minutes) comparable
with indomethacin (baseline 1.72 ± 0.88 ng/mL/hour,
furosemide-stimulated PRA maximum 2.58 ± 1.26 ng/
mL/hour at 120 minutes).
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Fig. 1. Effects of celecoxib 200 mg twice a day (b.i.d.), indomethacin 50 mg three times a day (t.i.d.), or placebo on plasma renin activity on day
5 of treatment before (pre) and 5, 10, 30, 60, and 120 minutes after furosemide 20 mg intravenously. Mean ± SE (N = 16). ∗P < 0.05; ∗∗P < 0.001
versus placebo, same time point; †P < 0.05; ††P <0.001 versus prefurosemide, same medication.
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Fig. 2. Effects of celecoxib 200 mg twice a day (b.i.d.), indomemacin 50 mg three times a day (t.i.d.), or placebo on plasma aldosterone concentration
on day 5 of treatment before (pre) and 5, 10, 30, 60, and 120 minutes after 20 mg intravenously. Mean ± SE (N = 16). ∗P < 0.05; ∗∗P < 0.001 versus
placebo, same time point; †P < 0.05; ††P <0.001 versus prefurosemide, same medication.
Plasma aldosterone concentration
The results for plasma aldosterone concentration are
shown in Figure 2. The normal range for aldosterone
in the radioimmunoassay used is 34 to 273 pg/mL in
upright position and 10 to 105 pg/mL in supine posi-
tion. As observed for PRA, the inhibition of baseline
and furosemide-stimulated plasma aldosterone concen-
tration by celecoxib was comparable with the effect
of indomethacin. In contrast to the immediate reac-
tion of PRA, the increase of plasma aldosterone after
furosemide was delayed and less affected by celecoxib or
indomethacin.
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Table 1. Effects of celecoxib 200 mg twice a day (b.i.d.), indomethacin 50 mg three times a day (t.i.d.), or placebo on urine volume, potassium,
sodium, and creatinine excretion in 24-hour urine on the day 4 of treatment and in 2-hour urine on the day 5 before and after 20 mg furosemide
intravenously
Urine volume mL Urinary potassium mmol Urinary sodium mmol Urinary creatinine mmol
Placebo 24-hour urine on day 4 1913 ± 589 69.8 ± 17.7 121.1 ± 41.9 10.7 ± 2.5
2 hours before furosemide 223 ± 165 5.8 ± 3.7 7.9 ± 5.2 1.1 ± 0.4
2 hours after furosemide 720 ± 196b 18.2 ± 5.2b 81.6 ± 25.9b 1.3 ± 0.2
Celecoxib 24-hour urine on day 4 2086 ± 750 70.9 ± 29.1 138.2 ± 49.1 11.3 ± 2.1
2 hours before furosemide 246 ± 157 6.1 ± 3.1 10.2 ± 6.9 1.3 ± 0.3
2 hours after furosemide 723 ± 239b 15.3 ± 5.2a,b 84.9 ± 28.2b 1.3 ± 0.2
Indomethacin 24-hour urine on day 4 1909 ± 632 73.2 ± 13.9 137.0 ± 48.6 11.1 ± 1.7
2 hours before furosemide 283 ± 180 7.9 ± 3.7 10.1 ± 8.6 1.2 ± 0.3
2 hours after furosemide 724 ± 252b 16.8 ± 6.2a,b 86.1 ± 30.1b 1.3 ± 0.1
Mean ± SD (N = 17) (24-hour urines) (N = 16) (2-hour urines), respectively.
aP < 0.05 versus placebo, same collection period; bP < 0.001 versus 2 hours before furosemide, same medication.
Potassium, sodium, creatinine in urine and serum, urine
volume, and body weight
Potassium, sodium, and creatinine in urine, urine vol-
ume. Urinary excretion of sodium, potassium and crea-
tinine in 24-hour urine on day 4 and 2 hour urine before
furosemide were not different between placebo, cele-
coxib, and indomethacin (Table 1). Twenty-four–hour
sodium excretion in all treatment phases was consistent
with the estimated sodium intake of 117 to 139 mmol/
day. As expected, in 2-hour urine after furosemide uri-
nary potassium and sodium excretion were increased.
Celecoxib and indomethacin significantly attenuated the
increase of potassium excretion, whereas for sodium ex-
cretion no differences between study drugs were ob-
served. Urinary creatinine excretion in 2-hour urine after
furosemide was not changed. Urine volume of 24-hour
urine, 2-hour urine before and after furosemide was not
influenced by placebo, celecoxib, or indomethacin.
Potassium, sodium, and creatinine in serum. The con-
centrations of sodium, potassium and creatinine in serum
remained within the normal range throughout the study
(Fig. 3). In comparison with placebo, serum potassium
concentration before furosemide was significantly higher
with celecoxib; a similar, but nonsignificant, trend was
observed for indomethacin. After furosemide, there was
a trend toward reduction of serum potassium concen-
trations in all treatment groups, which became signifi-
cant only for celecoxib 120 minutes after furosemide. In
comparison with placebo, higher serum potassium was
observed with both active treatments at 60 and 120 min-
utes. Serum sodium concentrations did not change at all.
Serum creatinine 30, 60, and 120 minutes after furosemide
was significantly higher as compared to prefurosemide,
with no difference between the treatment groups.
Body weight. No effects of celecoxib (day 1 66.6 ±
10.2 kg and day 5 66.8 ± 10.2 kg) or indomethacin (day 1
67.0±10.6 kg and day 5 66.8±10.1 kg) on body weight be-
fore furosemide were observed (placebo day 1 66.3 kg ±
10.0 kg and day 5 66.9 ± 10.0 kg). There was an expected
reduction of body weight after furosemide in all treat-
ment groups, which was significantly attenuated by cele-
coxib and indomethacin (placebo −1.1 ± 0.3 kg, celecoxib
−0.9 ± 0.4 kg, and indomethacin −0.9 ± 0.3 kg) (P <
0.001 vs. prefurosemide, each) (P < 0.05 celecoxib and
indomethacin vs. placebo).
Prostanoids in urine
Urinary PGE2 excretion. Celecoxib had no significant
effect on PGE2 excretion in 24-hour urine, whereas in-
domethacin reduced it by 40% (Fig. 4). A similar re-
sult was found in the 2-hour urine before furosemide
(Table 2). The application of furosemide had no effect on
PGE2 excretion in urine collected in the following 2 hours
(Table 2). In contrast to the 24-hour urine and 2-hour
urine before furosemide, celecoxib caused a reduction of
urinary PGE2 excretion after furosemide (Table 2).
Urinary PGE-M excretion. PGE-M excretion in 24-h
urine was reduced by indomethacin, whereas celecoxib
showed no significant effect (Fig. 5). The same result was
found in the 2-hour urine before furosemide (Table 2).
Furosemide led to an increase of PGE-M excretion in
urine collected in the following 2-hour in all treatment
groups (Table 2); however, the inhibitory effect of in-
domethacin was still evident.
Urinary excretion of 2,3-dinor-6-keto-PGF1a and 6-
keto-PGF1a . Celecoxib as well as indomethacin led to
a 60% reduction of 2,3-dinor-6-keto-PGF1a (Fig. 6) and
a 40% reduction of 6-keto-PGF1a excretion (Fig. 7) in
24-hour urine. The same result was found in the 2-hour
urine before furosemide, however, with a greater vari-
ability (Table 2). After furosemide, in the placebo treat-
ment period a decrease of 2,3-dinor-6-keto-PGF1a and
6-keto-PGF1a excretion was observed in urine collected
in the following 2 hours (Table 2). Again, compared
with placebo, both active treatments caused a reduction
of urinary 2,3-dinor-6-keto-PGF1a and 6-keto-PGF1a
excretion.
Urinary excretion of 2,3-dinor-TxB2. 2,3-dinor-TxB2
excretion in 24-hour urine was markedly inhibited by
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Fig. 3. Effects of celecoxib 200 mg twice a day (b.i.d.) (), indomethacin 50 mg three times a day (t.i.d.) (∆), or placebo (◦) on potassium
(A), sodium (B), and creatinine (C) concentration in serum on day 5 of treatment before, 5, 10, 30, 60, and 120 minutes after 20 mg furosemide
intravenously. Mean ± SE (N = 16). ∗P < 0.05; ∗∗P < 0.001 versus placebo, same time point; †P < 0.05; ††P <0.001 versus before furosemide, same
medication.
Stichtenoth et al: Celecoxib effects on renin and prostanoids 2203
Table 2. Effects of celecoxib 200 mg twice a day (b.i.d.), indomethacin 50 mg three times a day (t.i.d.) or placebo on excretion of prostaglandin E2
(PGE2), 7a-hydroxy-5,11-diketotetranor-prosta-1,16-dioic acid (PGE-M), 6-keto-PGF1a , 2,3-dinor-6-keto-PGF1a , and 2,3-dinor-thromboxane B2
(TxB2) in 2-hour urines on the day 5 of treatment before and after 20 mg furosemide intravenously
PGE2 nmol/mol PGE-M nmol/mol 6-keto-PGF1a nmol/mol 2,3-dinor-6-keto-PGF1a 2,3-dinor-TxB2 nmol/mol
creatinine creatinine creatinine nmol/mol creatinine creatinine
Placebo
2 hours before furosemide 78.9 ± 46.7 330.8 ± 181.1 34.6 ± 19.2 58.9 ± 31.9 134.2 ± 75.7
2 hours after furosemide 78.8 ± 39.4 795.6 ± 413.0f 27.7 ± 17.8e 36.7 ± 23.5e 104.9 ± 97.0
Celecoxib
2 hours before furosemide 65.3 ± 62.6c 217.8 ± 107.3c 19.5 ± 11.7a 14.7 ± 7.4b 112.3 ± 63.7d
2 hours after furosemide 45.6 ± 19.3a 536.2 ± 276.4c,f 14.8 ± 7.9a,c 20.0 ± 15.8e,c 108.2 ± 58.9d
Indomethacin
2 hours before furosemide 33.0 ± 9.9b 146.9 ± 85.2b 20.3 ± 13.9a 15.5 ± 33.4b 16.9 ± 10.7b
2 hours after furosemide 34.6 ± 12.0b 337.9 ± 182.7b,f 10.5 ± 7.8b,e 5.4 ± 3.9b 19.7 ± 15.5a
Mean ± SD (N = 16).
aP < 0.05; bP < 0.001 versus placebo, same collection period; cP < 0.05; dP < 0.001 versus indomethacin, same collection period; eP < 0.05; and fP < 0.001 vs. 2-hour
urine before furosemide, same medication.
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Fig. 4. Effects of celecoxib 200 twice a day (b.i.d.), indomethacin 50
mg three times a day (t.i.d.), or placebo on prostaglandin E2 (PGE2)
excretion in 24-hour urine on day 4 of treatment. Mean ± SE (N = 17)
∗∗P < 0.001 versus placebo; #P < 0.05 vs. celecoxib.
indomethacin, but remained unaffected by celecoxib
(Fig. 6). The same result was found in the 2-hour urines
before and after furosemide (Table 2).
DISCUSSION
This is the first study to demonstrate inhibition of
baseline and furosemide stimulated renin release by
a specific COX-2 inhibitor in healthy volunteers with
normal salt intake. The consistent effects of celecoxib
on renin release, aldosterone and potassium concentra-
tion in plasma, and urinary potassium excretion were
comparable with the effects of the COX-unselective
indomethacin.
Inhibition of baseline and furosemide-stimulated PRA
in healthy volunteers with normal salt intake was repet-
itively shown for indomethacin, ibuprofen, and sulindac
[14, 21–23], but not for the preferential COX-2 inhibitors
meloxicam or etodolac [12, 23]. In the original study, on
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Fig. 5. Effects of celecoxib 200 mg twice a day (b.i.d.), indomethacin 50
three times a day (t.i.d.), or placebo on 7a-hydroxy-5,11-diketotetranor-
prosta-1,16-dioic acid (PGE-M) excretion in 24-hour urine on day 4 of
treatment. Mean ± SE (N = 17). ∗∗P < 0.001 versus placebo; #P < 0.05
versus celecoxib.
discovering the inhibition of baseline and furosemide-
stimulated PRA by a NSAID [14], we assessed PRA in
resting volunteers in upright position, leading to a higher
baseline PRA as compared with PRA in supine position.
Different study conditions with regard to posture may
explain the varying results of NSAIDs on baseline PRA
(e.g., in our previous study neither meloxicam nor in-
domethacin had an effect on supine PRA) [12].
Since the present study was conducted in young
women, the influence of sex hormones on PRA during the
menstrual cycle is a potential biasing factor. As demon-
strated by Pechere-Bertschi et al [24] PRA is higher in
the follicular than in the luteal phase; use of oral contra-
ceptives increases PRA. To control the influence of sex
hormones we enrolled only users of oral contraceptives
to ensure stable cycles and adapted the randomized study
treatment to the apparent menstrual cycle. In confirma-
tion, no sequence effects were observed.
2204 Stichtenoth et al: Celecoxib effects on renin and prostanoids
2,3-dinor-6-keto-PGF1α
2,3-dinor-TXB2
Indomethacin
50 mg t.i.d.
Celecoxib
200 mg b.i.d.
Placebo
**
**
**
##
140
120
100
80
60
40
20
0
2,
3-
di
no
r-T
XB
2,
 
n
m
o
l/m
ol
 c
re
at
in
in
e
2,
3-
di
no
r-6
-k
et
o-
PG
F 1
α
,
 
n
m
o
l/m
ol
 c
re
at
in
in
e
60
50
40
30
20
10
0
Fig. 6. Effects of celecoxib 200 mg twice a day (b.i.d.), indomethacin 50 mg three times a day (t.i.d.), or placebo on 2,3-dinor-6-keto-PGF1a and
2,3-dinor-thromboxane B2 (TxB2) excretion in 24-hour urine on day 4 of treatment. Mean ± SE (N = 17). ∗∗P < 0.001 versus placebo; ##P < 0.001
versus celecoxib.
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Fig. 7. Effects of celecoxib 200 mg twice a day (b.i.d.), indomethacin
50 mg three times a day (t.i.d.), or placebo on 2,3-dinor-6-keto-PGF1a
excretion in 24-hour urine on day 4 of treatment. Mean ± SE (N = 17).
∗P < 0.05 versus placebo.
A further potentially confounding factor is the applica-
tion of furosemide. In rats, chronic infusion of furosemide
directly stimulates COX-2 expression in the macula densa
region by inhibition of salt transport in the loop of Henle
[25]. In addition, salt and volume depletion are involved
as secondary factors. In our study, the long intervals be-
tween the furosemide stimulation tests and the absence
of phase effects makes such a COX-2 up-regulation very
unlikely.
The present study elucidates the crucial role of COX-2
for renin release under physiologic conditions. The im-
pact of pathophysiologically increased COX-2 expression
in the macula densa is highlighted by the findings in pa-
tients with Bartter-like syndrome, a heterogeneous group
of inherited salt-losing tubulopathies. Salt and water loss
led to strong induction of COX-2 in the macula densa,
increased PGE2 excretion in urine, hyperreninemia, and
hyperaldosteronism with hypokalemia and metabolic al-
kalosis [7]. In these patients, inhibition of COX-2 by rofe-
coxib suppressed hyperreninemia, reduced urinary PGE2
excretion, and ameliorated the clinical symptoms [26].
Also the PRA increase in salt-depleted healthy volun-
teers was shown to be COX-2 dependent, because it could
be blocked by rofecoxib [13].
Another important finding of our study is the sparing
of baseline renal PGE2 production by celecoxib (−6%,
NS), whereas indomethacin led to a 40% reduction. For
interpretation, the small sample size and the great vari-
ation must be considered (difference to be detected see
statistical analysis). However, despite the limited power
of the study, it can be concluded that under physiologic
conditions the majority of renal PGE2 is synthesized by
COX-1. This is in agreement with the animal experimen-
tal findings [27, 28] and our clinical studies with meloxi-
cam, which in therapeutic dosage did not inhibit renal
PGE2 production in healthy young female volunteers
[12, 29]. However, celecoxib inhibited PGE2 excretion
in the 2-hour urine after furosemide by 42%. It is unclear
whether this result is by chance or is suggestive of a role
for constitutive COX-2 in adaptive PGE2 production. Re-
markably, in women older than 65 years with physiologic
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decline of renal function, sustained decreases of urinary
PGE2 excretion after administration of celecoxib 200 mg
twice a day and naproxen 500 mg twice a day for 5 days
were observed [30]. Two further studies which assessed
the effect of flosulide [11] and celecoxib [31] on urinary
PGE2 excretion included male volunteers, resulting in
high and varying PGE2 excretion rates due to contami-
nation of urine with seminal fluid. Similarly, the study by
Kammerl et al [13] included male volunteers and reported
only the combined excretion of PGE-M and PGE2.
Prostacyclin, the other major prostanoid in the kidney,
is assessed by measuring urinary 6-keto-PGF1a [17]. Un-
fortunately, this metabolite is only in part of renal origin
[17]. Bearing this methodologic limitation in mind, the
40% reduction of urinary 6-keto-PGF1a by celecoxib and
indomethacin suggests that COX-unselective and COX-
specific NSAIDs are alike in inhibition of renal prostacy-
clin production. Taking the effects on urinary PGE2 and
6-keto-PGF1a together, one may expect a gain in renal
safety by use of specific COX-2 inhibitors. In fact, even
twice the therapeutic dosage of celecoxib or rofecoxib
caused no decrease in GFR in healthy elderly volunteers
and salt-depleted, young, healthy volunteers [30, 32–34].
Both groups are at moderate risk for impairment of renal
hemodynamics by NSAIDs [4]. Yet, when a second risk
factor is present, such as older age plus sodium and vol-
ume depletion, specific COX-2 inhibition led to the same
reduction of GFR as indomethacin [35]. Moreover, tubu-
lar sodium excretion [30, 32–34] and PRA, as presented
in this paper, are similarly inhibited by specific COX-2
inhibitors and COX-unselective NSAIDs.
We also assessed the effect of specific COX-2 inhibi-
tion on systemic prostanoid production. Like renal PGE2,
whole body synthesis of E prostaglandins, reflected by
urinary PGE-M excretion, was not significantly reduced
by celecoxib, whereas indomethacin caused a decrease by
45%. However, we observed a strong, but nonsignificant,
trend toward reduction of urinary PGE-M excretion by
celecoxib before (−14% in 24-hour urine and −34% in
2-hour urine) and after furosemide (−33%). In line with
these results are the findings of Dilger et al [31], who re-
ported a 35% reduction of urinary PGE-M excretion in
young healthy volunteers treated for 15 days with cele-
coxib 200 mg twice a day. In contrast, the recently pub-
lished study by Murphey et al [36] found a 62% reduction
of urinary PGE-M excretion in healthy volunteers treated
with rofecoxib 50 mg/day for 4 days. Whether a stronger
COX-2 inhibition or special characteristics of the study
population (N = 9, not further characterized) explain this
divergent result is unclear. Altogether the current evi-
dence shows that at least a substantial portion of total
body production of E prostaglandins is COX-2 depen-
dent in healthy volunteers. In patients with inflamma-
tory diseases or cancer, COX-2 expression is elevated
[2]. Under this condition, the increased PGE2 produc-
tion is expected to be COX-2 dependent. In fact, the
aforementioned study by Murphy et al [36] determined a
greatly increased PGE-M excretion in patients with non-
small cancer of the lung. This increase was dramatically
reduced by treatment wit celecoxib 400 mg twice a day
[36].
Concerning celecoxib’s effects on whole body synthe-
sis of thromboxane and its physiologic antagonist prosta-
cyclin, we confirmed the well described characteristic
profile of a specific COX-2 inhibitor, which spares com-
pletely the COX-1–dependent thromboxane synthesis
and markedly inhibits prostacyclin formation [31, 32, 37].
This shift of the thromboxane/prostacyclin ratio toward
thromboxane by specific COX-2 inhibition could pose a
thrombogenic risk. After the withdrawal of rofecoxib, it is
intensely discussed whether this prothrombotic potential
translates into a higher rate of thromboembolic events
as a class effect of specific COX-2 inhibitors. Detailed
analysis of our present data contributes an important as-
pect to this discussion. In our study the normal ratio of
24-hour production of thromboxane/prostacyclin, set to
1 in placebo-treated volunteers, was changed to 2.5 by
celecoxib and to 0.5 by indomethacin. The same shift
of the thromboxane/prostacyclin ratio was observed by
Catella-Lawson et al [32] for rofecoxib 50 mg/day. Al-
though the urinary excretion of thromboxane metabolites
may not reflect minor variations in thromboxane produc-
tion as consequence of peak plasma drug concentrations,
substantial changes are unlikely [37]. Thus, given the
clear difference in cardiovascular risk between celecoxib
and rofecoxib [38–40], the cardiovascular risk of specific
COX-2 inhibitors cannot solely be explained by the ef-
fects on thromboxane and prostacyclin synthesis. Other
factors such as different effects on endothelial function
and blood pressure must be considered, too [39]. By blood
pressure elevation as common side effect, all NSAIDs
may promote heart failure, myocardial infarction and
stroke. In fact, a large federal Food and Drug Admin-
istration (FDA)–sponsored case control study revealed
an increased risk for myocardial infarction not only for
rofecoxib but also for naproxen, indomethacin, and pos-
sibly diclofenac [40]. Most recently, a placebo-controlled
long-term Alzheimer prevention study showed a higher
rate of cardiovascular events in patients taking naproxen
(FDA Statement on Naproxen, December 20, 2004).
CONCLUSION
Our study gives the functional proof that renal renin
release in healthy humans is COX-2 dependent. Thus,
specific COX-2 inhibitors may cause hyperkalemia,
particularly in patients with impaired renal function
or comedication with angiotensin-convertine enzyme
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(ACE) inhibitors, angiotensin type 1 (AT1) recep-
tor antagonists or potassium-sparing diuretics. Further-
more, the contribution of COX-1 and COX-2 to renal
and systemic prostanoid production is defined as fol-
lows: (1) COX-1 is critical for renal PGE2 production;
(2) renal prostacyclin production is suggested to be
COX-2–dependent; (3) COX-1 is the predominant en-
zyme for systemic PGE2 production; however, a signifi-
cant contribution of COX-2 is probable; and (4) COX-1
is responsible for total body thromboxane synthesis,
whereas COX-2 is crucial for prostacyclin synthesis.
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